Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy

10Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Monoclonal antibodies (mAb) are central to the treatment of several types of malignancy. However, these reagents are subject to particular types of resistance. Several resistance mechanisms are regulated by the inhibitory FcγRIIB. We recently developed mAbs to block FcγRIIB and provided in vivo proof-of-concept for their ability to overcome FcγRIIB-mediated resistance.

Cite

CITATION STYLE

APA

Roghanian, A., Cragg, M. S., & Frendéus, B. (2016). Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy. OncoImmunology, 5(2). https://doi.org/10.1080/2162402X.2015.1069939

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free